Recently, the first antibody-drug conjugates(ADCs), Trastuzumab emtansine, was approved in treating patients with HER2-positive locally advanced breast cancer which is unresectable [45–46], indicating a bright future of the utilization of ADCs in clinic . This evidence concerns the gene ERBB2 and breast cancer.